What is the prevalence of anabolic-androgenic steroid use among women? A systematic review.
anabolic‐androgenic steroids
doping
female
performance and image enhancing drugs
systematic review
women
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
27
03
2024
accepted:
26
06
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
aheadofprint
Résumé
Evidence suggests there has been an increase in anabolic-androgenic steroid (AAS) use among women, driven by the evolving landscape of women's participation in sport. However, the extent of use is unknown. This systematic review aimed to estimate the prevalence of women's AAS use. We conducted a systematic review of peer-reviewed articles in English, focusing on AAS use among women aged 18 and above. We excluded grey literature and studies that measured doping through some form of analysis (e.g. urine or hair). Searched databases were MEDLINE, CINAHL, PsycINFO, SocINDEX, SPORTDiscus, Embase and Cochrane Library. Titles and abstracts for all articles were screened, followed by full-text assessment and data extraction of included articles by multiple authors for accuracy. The pooled prevalence of lifetime use was determined using a random effects model and the risk of bias was assessed using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. Based on 18 studies, participant numbers averaged 669 per study (median = 189; range = 16 to 7051). The overall pooled AAS use prevalence was 4% (95% confidence interval [CI] = 2-9%) with high heterogeneity overall (I Anabolic-androgenic steroid use among women appears to be substantially higher among bodybuilders and athletes/recreational gym users than the general female population.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Evidence suggests there has been an increase in anabolic-androgenic steroid (AAS) use among women, driven by the evolving landscape of women's participation in sport. However, the extent of use is unknown. This systematic review aimed to estimate the prevalence of women's AAS use.
METHOD
METHODS
We conducted a systematic review of peer-reviewed articles in English, focusing on AAS use among women aged 18 and above. We excluded grey literature and studies that measured doping through some form of analysis (e.g. urine or hair). Searched databases were MEDLINE, CINAHL, PsycINFO, SocINDEX, SPORTDiscus, Embase and Cochrane Library. Titles and abstracts for all articles were screened, followed by full-text assessment and data extraction of included articles by multiple authors for accuracy. The pooled prevalence of lifetime use was determined using a random effects model and the risk of bias was assessed using the Joanna Briggs Institute Prevalence Critical Appraisal Tool.
RESULTS
RESULTS
Based on 18 studies, participant numbers averaged 669 per study (median = 189; range = 16 to 7051). The overall pooled AAS use prevalence was 4% (95% confidence interval [CI] = 2-9%) with high heterogeneity overall (I
CONCLUSION
CONCLUSIONS
Anabolic-androgenic steroid use among women appears to be substantially higher among bodybuilders and athletes/recreational gym users than the general female population.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Mean LJ, Kassing JW. “I would just like to be known as an athlete”: managing hegemony, femininity, and heterosexuality in female sport. Western J Commun. 2008;72(2):126–144. https://doi.org/10.1080/10570310802038564
Schippers M. Recovering the feminine other: masculinity, femininity, and gender hegemony. Theory Soc. 2007;36(1):85–102. https://doi.org/10.1007/s11186-007-9022-4
Henning A, Andreasson J. Preventing, producing, or reducing harm? Fitness doping risk and enabling environments. Drugs: Educ Prev Pol. 2022;29(1):95–104.
Krane V. We can be athletic and feminine, but do we want to? Challenging hegemonic femininity in women's sport. Quest. 2001;53(1):115–133. https://doi.org/10.1080/00336297.2001.10491733
Piatkowski T, Robertson J, Lamon S, Dunn M. Gendered perspectives on women's anabolic–androgenic steroid (AAS) usage practices. Harm Reduct J. 2023;20(1):1–11. https://doi.org/10.1186/s12954-023-00786-x
Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996–1998. Ann Intern Med. 2001;134(4):282–286. https://doi.org/10.7326/0003-4819-134-4-200102200-00011
Piatkowski TM, Neumann DL, Seekis V, Dunn M. Understanding muscularity, physique anxiety, and the experience of body image enhancement among men and women: a mixed‐methods study. J Community Appl Soc Psychol. 2024;34(3):e2800. https://doi.org/10.1002/casp.2800
Robinson L, Prichard I, Nikolaidis A, Drummond C, Drummond M, Tiggemann M. Idealised media images: the effect of fitspiration imagery on body satisfaction and exercise behaviour. Body Image. 2017;22:65–71. https://doi.org/10.1016/j.bodyim.2017.06.001
Abrahin O, Félix Souza NS, de Sousa EC, Santos AM, Bahrke MS. Anabolic–androgenic steroid use among Brazilian women: an exploratory investigation. J Subst Abuse. 2017;22(3):246–252. https://doi.org/10.1080/14659891.2016.1179806
Ip EJ, Barnett MJ, Tenerowicz MJ, Kim JA, Wei H, Perry PJ. Women and anabolic steroids: an analysis of a dozen users. Clin J Sport Med. 2010;20(6):475–481. https://doi.org/10.1097/JSM.0b013e3181fb5370
Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non‐athletes. Mol Cell Endocrinol. 2018;464:4–13. https://doi.org/10.1016/j.mce.2017.02.039
Gibbs N, Piatkowski T. The liver king lie: misrepresentation, justification, and public health implications. Int J Drug Policy. 2023;114:103979. https://doi.org/10.1016/j.drugpo.2023.103979
Gibbs N, Salinas M, Turnock L. Post‐industrial masculinities and gym culture: graft, craft, and fraternity. Br J Sociol. 2022;73(1):220–236. https://doi.org/10.1111/1468-4446.12921
Hearne E, Atkinson A, Boardley I, McVeigh J, Van Hout MC. ‘Sustaining masculinity’: a scoping review of anabolic androgenic steroid use by older males. Drugs: Educ Prev Pol. 2022;1–27.
Piatkowski TM, White KM, Hides LM, Obst PL. Australia's Adonis: understanding what motivates young men's lifestyle choices for enhancing their appearance. Aust Psychol. 2020;55(2):156–168. https://doi.org/10.1111/ap.12451
Dunn M, Piatkowski TM, Robertson J, Lamon S. Is the use of performance and image enhancing drugs (PIEDs) in women an issue of concern? The findings from a stakeholder consultation. J Sci Med Sport. 2023;26(11):574–579. https://doi.org/10.1016/j.jsams.2023.08.179
Börjesson A, Ekebergh M, Dahl M‐L, Ekström L, Lehtihet M, Vicente V. Women's experiences of using anabolic androgenic steroids. Front Sports Active Living. 2021;3:656413. https://doi.org/10.3389/fspor.2021.656413
Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic‐androgenic steroid use: a meta‐analysis and meta‐regression analysis. Ann Epidemiol. 2014;24(5):383–398. https://doi.org/10.1016/j.annepidem.2014.01.009
Piatkowski T, Dunn M. Navigating Risks and Reducing Harm: A Gendered Analysis of Anabolic–Androgenic Steroid Users Within the Risk Environment Framework. Contemp Drug Probl. 2024;00914509241249292.
Havnes IA, Jørstad ML, Innerdal I, Bjørnebekk A. Anabolic‐androgenic steroid use among women–a qualitative study on experiences of masculinizing, gonadal and sexual effects. Int J Drug Policy. 2021;95:102876. https://doi.org/10.1016/j.drugpo.2020.102876
Kotzé J, Richardson A, Antonopoulos GA. Looking ‘acceptably'feminine: a single case study of a female bodybuilder's use of steroids. Perform Enhanc Health. 2020;8(2–3):100174. https://doi.org/10.1016/j.peh.2020.100174
Börjesson A, Gårevik N, Dahl M‐L, Rane A, Ekström L. Recruitment to doping and help‐seeking behavior of eight female AAS users. Subst Abuse Treat Prev Policy. 2016;11(1):1–6. https://doi.org/10.1186/s13011-016-0056-3
Piatkowski T, Whiteside B, Robertson J, Lamon S, Dunn M. Performance and image enhancing drug use among Australian women: The role of interpersonal relationships in facilitating use. Contemp Drug Probl. 2024;00914509241256002.
Henning A, Andreasson J. “Yay, another lady starting a log!”: Women's fitness doping and the gendered space of an online doping forum. Commun Sport. 2021;9(6):988–1007. https://doi.org/10.1177/2167479519896326
Paul RW, Sonnier JH, Johnson EE, Hall AT, Osman A, Connors GM, et al. Inequalities in the evaluation of male versus female athletes in sports medicine research: a systematic review. Am J Sports Med. 2023;51(12):3335–3342. https://doi.org/10.1177/03635465221131281
Smith ES, McKay AK, Kuikman M, Ackerman KE, Harris R, Elliott‐Sale KJ, et al. Auditing the representation of female versus male athletes in sports science and sports medicine research: evidence‐based performance supplements. Nutrients. 2022;14(5):953. https://doi.org/10.3390/nu14050953
Zahnow R, McVeigh J, Bates G, Hope V, Kean J, Campbell J, et al. Identifying a typology of men who use anabolic androgenic steroids (AAS). Int J Drug Policy. 2018;55:105–112. https://doi.org/10.1016/j.drugpo.2018.02.022
Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men's use of anabolic androgenic steroids in fitness and strength training environments. Drugs: Educ Prev Pol. 2017;24(3):295–305.
Börjesson A, Lehtihet M, Andersson A, Dahl ML, Vicente V, Ericsson M, et al. Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents. Drug Test Anal. 2020;12(4):514–523. https://doi.org/10.1002/dta.2763
Havnes IA, Muller AE. Nonprescribed androgen use among women and trans men. Curr Opin Endocrinol Diabetes Obes. 2021;28(6):595–603. https://doi.org/10.1097/MED.0000000000000680
Kanayama G, Boynes M, Hudson JI, Field AE, Pope HG Jr. Anabolic steroid abuse among teenage girls: an illusory problem? Drug Alcohol Depend. 2007;88(2–3):156–162. https://doi.org/10.1016/j.drugalcdep.2006.10.013
Dunn M, Whiteside B. Investigating the capacity of Australian drug information systems to detect changes in anabolic‐androgenic steroid use and harms. Performance Enhancement & Health. 2023 Jun 1;11(2):100249.
Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123–128. https://doi.org/10.15171/ijhpm.2014.71
Sawyer S, Cowlishaw S, Kendrick K, Boyle M, Dicker B, Lord B. Systematic review of incidence, prevalence, and trends in health outcomes for Australian and New Zealand paramedics. Prehosp Emerg Care. 2023;27(4):398–412. https://doi.org/10.1080/10903127.2022.2064019
Goldfield GS. Body image, disordered eating and anabolic steroid use in female bodybuilders. Eat Disord. 2009;17(3):200–210. https://doi.org/10.1080/10640260902848485
Gruber AJ, Pope HG Jr. Psychiatric and medical effects of anabolic‐androgenic steroid use in women. Psychother Psychosom. 2000;69(1):19–26. https://doi.org/10.1159/000012362
Tricker R, Cook DL, McGuire R. Issues related to drug abuse in college athletics: athletes at risk. Sport Psychol. 1989;3(2):155–165. https://doi.org/10.1123/tsp.3.2.155
Wright S, Grogan S, Hunter G. Motivations for anabolic steroid use among bodybuilders. J Health Psychol. 2000;5(4):566–571. https://doi.org/10.1177/135910530000500413
Khullar N, Scull NC, Deeny MC, Hamdan E. Prevalence and predictors of anabolic‐androgenic steroid use among gym users in Kuwait: a preliminary study. Int J Men's Health. 2016;15(2):144–156.
Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med. 1997;18(07):557–562. https://doi.org/10.1055/s-2007-972681
Leifman H, Rehnman C, Sjöblom E, Holgersson S. Anabolic androgenic steroids—use and correlates among gym users—an assessment study using questionnaires and observations at gyms in the Stockholm region. Int J Environ Res Public Health. 2011;8(7):2656–2674. https://doi.org/10.3390/ijerph8072656
Malone DA Jr, Dimeff RJ, Lombardo JA, Sample RB. Psychiatric effects and psychoactive substance use in anabolic‐androgenic steroid users. Clin J Sport Med. 1995;5(1):25–31. https://doi.org/10.1097/00042752-199501000-00005
Ohaeri JU, Ikpeme E, Ikwuagwu PU, Zamani A, Odejide OA. Use and awareness of effects of anabolic steroids and psychoactive substances among a cohort of Nigerian professional sports men and women. Human Psychopharmacol: Clin Exp. 1993;8(6):429–432. https://doi.org/10.1002/hup.470080609
Striegel H, Simon P, Frisch S, Roecker K, Dietz K, Dickhuth H‐H, et al. Anabolic ergogenic substance users in fitness‐sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81(1):11–19. https://doi.org/10.1016/j.drugalcdep.2005.05.013
Vaskinn A, Hauger LE, Bjørnebekk A. Theory of mind in users of anabolic androgenic steroids. Psychopharmacology (Berl). 2020;237(10):3191–3199. https://doi.org/10.1007/s00213-020-05603-y
Berning JM, Adams KJ, DeBeliso M, Stamford BA, Newman IM. Anabolic androgenic steroids: use and perceived use in nonathlete college students. J Am Coll Health. 2008;56(5):499–504. https://doi.org/10.3200/JACH.56.5.499-504
Hakansson A, Mickelsson K, Wallin C, Berglund M. Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res. 2012;18(2):83–90. https://doi.org/10.1159/000333037
Havnes IA, Bukten A, Rognli EB, Muller AE. Use of anabolic‐androgenic steroids and other substances prior to and during imprisonment‐results from the Norwegian offender mental health and addiction (NorMA) study. Drug Alcohol Depend. 2020;217:108255. https://doi.org/10.1016/j.drugalcdep.2020.108255
Lundholm L, Käll K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010;111(3):222–226. https://doi.org/10.1016/j.drugalcdep.2010.04.020
Nagata JM, Peebles R, Hill KB, Gorrell S, Carlson JL. Associations between ergogenic supplement use and eating behaviors among university students. Eat Disord. 2021;29(6):599–615. https://doi.org/10.1080/10640266.2020.1712637
Rachoń D, Pokrywka L, Suchecka‐Rachoń K. Prevalence and risk factors of anabolic‐androgenic steroids (AAS) abuse among adolescents and young adults in Poland. Sozial‐Und Präventivmedizin SPM. 2006;51(6):392–398. https://doi.org/10.1007/s00038-006-6018-1
Chananie‐Hill RA, McGrath SA, Stoll J. Deviant or normal? Female bodybuilders' accounts of social reactions. Deviant Behav. 2012;33(10):811–830. https://doi.org/10.1080/01639625.2011.647592
McGrath SA, Chananie‐Hill RA. “Big freaky‐looking women”: normalizing gender transgression through bodybuilding. Sociol Sport J. 2009;26(2):235–254. https://doi.org/10.1123/ssj.26.2.235
Havnes IA, Jørstad ML, Bjørnebekk A. Double trouble? A mixed methods study exploring experiences with combined use of anabolic‐androgenic steroids and psychoactive substances among women. Perform Enhanc Health. 2021;9(3–4):100198. https://doi.org/10.1016/j.peh.2021.100198
Piatkowski T, Dunn M. Navigating Risks and Reducing Harm: A Gendered Analysis of Anabolic–Androgenic Steroid Users Within the Risk Environment Framework. Contemp Drug Probl. 2024;51(2):111–128. https://doi.org/10.1177/00914509241249292
Piatkowski T, Robertson J, Dunn M. Polysubstance use practices among women using anabolic‐androgenic steroids (AAS). Perform Enhanc Health. 2023;11(2):100248. https://doi.org/10.1016/j.peh.2023.100248
Scarth M, Jørstad ML, Reierstad A, Klonteig S, Torgersen S, Hullstein IR, et al. Psychopathology among anabolic‐androgenic steroid using and non‐using female athletes in Norway. J Psychiatr Res. 2022;155:295–301. https://doi.org/10.1016/j.jpsychires.2022.09.023
Campbell F, Haverda MB, Bartkowski JP. Rival bodies: negotiating gender and embodiment in women's bikini and figure competitions. Soc Sci. 2021;10(2):64. https://doi.org/10.3390/socsci10020064
Gibson K, Hutton F. Women who inject drugs (WWID): stigma, gender and barriers to needle exchange programmes (NEPs). Contemp Drug Probl. 2021;48(3):276–296. https://doi.org/10.1177/00914509211035242
Ataiants J, Roth AM, Mazzella S, Lankenau SE. Circumstances of overdose among street‐involved, opioid‐injecting women: drug, set, and setting. Int J Drug Policy. 2020;78:102691. https://doi.org/10.1016/j.drugpo.2020.102691
Spooner C, Saktiawati AMI, Lazuardi E, Worth H, Subronto YW, Padmawati RS. Impacts of stigma on HIV risk for women who inject drugs in Java: a qualitative study. Int J Drug Policy. 2015;26(12):1244–1250. https://doi.org/10.1016/j.drugpo.2015.07.011
Atkinson A, Van De Ven K, Cunningham M, de Zeeuw T, Hibbert E, Forlini C, et al. Performance and image enhancing drug interventions aimed at increasing knowledge among healthcare professionals (HCP): reflections on the implementation of the Dopinglinkki e‐module in Europe and Australia in the HCP workforce. Int J Drug Policy. 2021;95:103141. https://doi.org/10.1016/j.drugpo.2021.103141
Eu B, Dawe J, Dunn M, Lee K, Griffiths S, Bloch M, et al. Impact of harm reduction practice on the use of non‐prescribed performance‐and image‐enhancing drugs: the PUSH! Audit Aust J Gen Practice. 2023;52(4):197–202. https://doi.org/10.31128/AJGP-04-22-6402
van de Ven K, Eu B, Jackson E, Han E, Gouda N, Simmonds P, et al. GP guide to harm minimisation for patients using non‐prescribed anabolic‐androgenic steroids (AAS) and other performance and image enhancing drugs (PIEDs) Sydney: Sydney North Health Network; 2020.